Caio Max Rocha Lima, MD
Hematology & Oncology · Winston Salem, NCNPI 1023040094
Payments from drug & device makers
Across 360 payments — averaging $7278.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.5M
- Genentech, Inc.$692K
- Merck$134K
- Incyte Corporation$112K
- Eisai Inc.$44K
- AstraZeneca$39K
- plus $128K from 13 others
Across 1 payment — averaging $2866.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 52 | $1,471,402 |
| Genentech, Inc. | 9 | $691,812 |
| Merck | 58 | $133,531 |
| Incyte Corporation | 116 | $112,429 |
| Eisai Inc. | 54 | $44,076 |
| AstraZeneca | 6 | $38,619 |
| Seagen Inc. | 18 | $35,803 |
| Pharmacyclics LLC, An Abbvie Company | 13 | $27,201 |
| Alkermes, Inc. | 4 | $20,465 |
| Bristol Myers Squibb | 12 | $13,777 |
| Ipsen Bioscience Inc. | 1 | $12,160 |
| Taiho Oncology, Inc. | 4 | $6,576 |
| Ipsen Biopharmaceuticals, Inc | 2 | $4,170 |
| Agios Pharmaceuticals, Inc. | 5 | $4,017 |
| Jazz Pharmaceuticals Inc. | 1 | $3,296 |
| Exelixis Inc. | 2 | $478 |
| Genentech USA, Inc. | 1 | $115 |
| Gilead | 1 | $102 |
| Astellas Pharma US Inc | 1 | $75 |
How this compares
$2,620,106 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Winston Salem
- Matthew WieduwiltWinston Salem$9.5M
- John McKayWinston Salem$2.9M
- Michael GoodmanWinston Salem$2.3M
- Rakhee VaidyaWinston Salem$2.3M
- Ravi PaluriWinston Salem$2.3M
- Leon Bernal-MizrachiWinston Salem$1.9M
- Michael McCormackWinston Salem$1.7M
- Angela AlistarWinston Salem$1.5M
- William PettyWinston Salem$1.4M
- Mary SeegarsWinston Salem$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.